[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342025-105":59,"doc-detail-342025-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","polo-like-kinase-1-predicts-lymph-node-metastasis-in-middle-eastern-colorectal-cancer-patients-its-inhibition-reverses-5-fu-resistance-in-colorectal-cancer-cells","Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients - Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells","","Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase that coordinates mammalian cell-cycle progression, and aberrant PLK1 regulation is associated with poor outcomes in many human cancers. This study clarifies PLK1’s role in Middle Eastern colorectal cancer by linking PLK1 overexpression with aggressive clinicopathological features and lymph node metastasis. In vitro, high PLK1 confers resistance to 5-Fu, whereas PLK1 inhibition by volasertib restores sensitivity and suppresses CRAF-MEK-ERK signaling, EMT progression, and stem-like traits.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/polo-like-kinase-1-predicts-lymph-node-metastasis-in-middle-eastern-colorectal-cancer-patients-its-inhibition-reverses-5-fu-resistance-in-colorectal-cancer-cells/342025/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/polo-like-kinase-1-predicts-lymph-node-metastasis-in-middle-eastern-colorectal-cancer-patients-its-inhibition-reverses-5-fu-resistance-in-colorectal-cancer-cells/342025.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical association does PLK1 show in Middle Eastern colorectal cancer patients?","Question",{"text":112,"@type":113},"PLK1 overexpression is reported in 60.3% of CRC cases and is significantly associated with aggressive clinico-pathological parameters and p-ERK1/2 overexpression, with PLK1 identified as an independent predictor of lymph node metastasis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PLK1 affect response to 5-Fu in CRC cells?",{"text":117,"@type":113},"CRC cells with high PLK1 levels resist 5-Fu treatment, while cells with low PLK1 expression are sensitive. The PLK1 inhibitor volasertib effectively reverses 5-Fu resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling pathway and cellular processes are influenced by PLK1 inhibition?",{"text":121,"@type":113},"Forced PLK1 expression activates the CRAF-MEK-ERK cascade, whereas its inhibition suppresses this signaling. PLK1 knockdown reduces EMT progression and stem cell-like traits in 5-Fu-resistant CRC cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342025,1790298748,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","cells  \nArticle  \nPolo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells  \nPratheesh Kumar Poyil 1,†, Abdul K. Siraj 1,†, Divya Padmaja 1, Sandeep Kumar Parvathareddy 1, Khadija Alobaisi 1, Saravanan Thangavel 1, Rafia Begum 1, Roxanne Diaz 1, Fouad Al-Dayel 2 and Khawla S. Al-Kuraya 1, *  \nCitation: Poyil, P.K.; Siraj, A.K.; Padmaja, D.; Parvathareddy, S.K.; Alobaisi, K.; Thangavel, S.; Begum, R.; Diaz, R.; Al-Dayel, F.; Al-Kuraya, K.S. Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells. Cells 2024, 13, 1700. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells13201700  \nAcademic Editors: Kazuyuki Kitatani and Daria A. Chudakova  \nReceived: 3 September 2024  \nRevised: 8 October 2024  \nAccepted: 11 October 2024  \nPublished: 14 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia; [ppoyil@kfshrc.edu.sa](ppoyil@kfshrc.edu.sa) (P.K.P.); [asiraj@kfshrc.edu.sa](asiraj@kfshrc.edu.sa) (A.K.S.); [dvsasidharan50@gmail.com](dvsasidharan50@gmail.com) (D.P.); [psandeepkumar@kfshrc.edu.sa](psandeepkumar@kfshrc.edu.sa) (S.K.P.); [kalobaisi@kfshrc.edu.sa](kalobaisi@kfshrc.edu.sa) (K.A.); tsaravanan97@kfshrc.edu.sa (S.T.); brafia@kfshrc.edu.sa (R.B.); rmelosantos87@kfshrc.edu.sa (R.D.)  \n2 Department of Pathology, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia; [dayelf@kfshrc.edu.sa](dayelf@kfshrc.edu.sa)  \n* Correspondence: [kkuraya@kfshrc.edu.sa](kkuraya@kfshrc.edu.sa); Tel.: +966-1-205-5167 † These authors contributed equally to this work.  \nAbstract: Polo-like kinase 1 (PLK1) is a serine/threonine–protein kinase essential for regulating multiple stages of cell cycle progression in mammals. Aberrant regulation of PLK1 has been observed in numerous human cancers and is linked to poor prognoses. However, its role in the pathogenesis of colorectal cancer (CRC) in the Middle East remains unexplored. PLK1 overexpression was noted in 60.3%(693/1149) of CRC cases and was significantly associated with aggressive clinico-pathological parameters and p-ERK1/2 overexpression. Intriguingly, multivariate logistic regression analysis identified PLK1 as an independent predictor of lymph node metastasis. Our in vitro experiments demonstrated that CRC cells with high PLK1 levels were resistant to 5-Fu treatment, while those with low PLK1 expression were sensitive. To investigate PLK1′ s role in chemoresistance, we used the specific inhibitor volasertib, which effectively reversed 5-Fu resistance. Interestingly, forced PLK1 expression activated the CRAF-MEK-ERK signaling cascade, while its inhibition suppressed this cascade. PLK1 knockdown reduced epithelial-to-mesenchymal transition (EMT) progression and stem cell-like traits in 5-Fu-resistant cells, implicating PLK1 in EMT induction and stemness in CRC. Moreover, silencing ERK1/2 significantly mitigated chemoresistance, EMT, and stemness properties in CRC cell lines that express PLK1 . Furthermore, the knockdown of Zeb1 attenuated EMT and stemness, suggesting a possible link between EMT activation and the maintenance of stemness in CRC. Our findings underscore the pivotal role of PLK1 in mediating chemoresistance and suggest that PLK1 inhibition may represent a potential therapeutic strategy for the management of aggressive colorectal cancer subtypes.  \nKeywords: PLK1;","cbCaiohR1k0d5YB8","https://ap.wps.com/l/cbCaiohR1k0d5YB8","pdf",6412955,16,"English","# Abstract\n# Introduction\n## Colorectal cancer burden and standard therapy\n## Chemoresistance and metastatic progression\n## EMT as a driver of metastasis\n## PLK1 in cancer progression","[{\"question\":\"What clinical association does PLK1 show in Middle Eastern colorectal cancer patients?\",\"answer\":\"PLK1 overexpression is reported in 60.3% of CRC cases and is significantly associated with aggressive clinico-pathological parameters and p-ERK1/2 overexpression, with PLK1 identified as an independent predictor of lymph node metastasis.\"},{\"question\":\"How does PLK1 affect response to 5-Fu in CRC cells?\",\"answer\":\"CRC cells with high PLK1 levels resist 5-Fu treatment, while cells with low PLK1 expression are sensitive. The PLK1 inhibitor volasertib effectively reverses 5-Fu resistance.\"},{\"question\":\"Which signaling pathway and cellular processes are influenced by PLK1 inhibition?\",\"answer\":\"Forced PLK1 expression activates the CRAF-MEK-ERK cascade, whereas its inhibition suppresses this signaling. PLK1 knockdown reduces EMT progression and stem cell-like traits in 5-Fu-resistant CRC cells.\"}]","Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients - Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells | PDF",1790044817,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b24000287ce9caf6d3e65394bfa53e5.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98d570f8613dac474510a96aae0f3a04.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea2be02e8c560ba63aef53caea2a478e.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/665e4e03135b6158dbd39340b05ebcbf.webp",980,1385]